Mesoblast (ASX:MSB) requested a Type B meeting with the US Food and Drug Administration to discuss the accelerated approval pathway for its drug candidate, Revascor, in treating ischemic chronic heart failure, according to a Thursday filing with the Australian bourse.
The meeting will focus on key aspects of the approval process, including manufacturing, potency assays, and confirmatory trial design, the filing said.
The meeting is expected to take place this quarter, the filing added.
Shares of the company fell nearly 2% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.